Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical and Molecular Hepatology|August 23, 2017
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal functionHyun Phil Shin, Ji-Ae Park, Blaire Burman, et al.
Colloids and Surfaces. B, Biointerfaces|December 10, 2020
Immobilisation of CXCL8 gradients in microfluidic devices for migration experimentsMichelle F Kilb, Victoria I Engemann, Asma Siddique, et al.
Journal of Clinical and Translational Research|November 15, 2021
Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosisNavroop Nagra, Rubal Penna, Danielle La Selva, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 26, 2013
Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidinAsma Siddique, James E Nelson, Bradley Aouizerat, et al.
Gut and Liver|June 27, 2017
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 PatientsHyun Phil Shin, Blaire Burman, Richard A Kozarek, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2016
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvirKris V Kowdley, David R Nelson, Jacob P Lalezari, et al.
Journal of Medical Virology|March 7, 2019
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapyFred Poordad, Michael Bennett, Thomas E Sepe, et al.
Journal of Viral Hepatitis|January 19, 2020
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trialsFred Poordad, RuiSarmento E Castro, Armen Asatryan, et al.
Journal of Autoimmunity|October 30, 2024
Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapyRitika Tewari, Soo Jung Yang, Ethan D McClain, et al.
Pageof 2